SpaceX's $123B Lockup Unlock Tests a Market Already Swimming in Supply

The US IPO market just set a record. It has also, quietly, set up a problem.

Three forces are converging in early August 2026: record equity issuance that has already surpassed the 2021 peak, a massive wave of lockup expirations headlined by SpaceX’s $123 billion unlock, and a buyback machine that is losing its ability to shrink share counts as AI infrastructure spending crowds out capital returns. Beneath all of this, the Federal Reserve’s overnight reverse repo facility has drained to roughly $1 billion — effectively zero — removing the system’s last liquidity shock absorber.

This is not a crisis signal. But the supply-demand math that has carried US equities to four consecutive years of double-digit gains is getting harder.

Record Issuance, Fewer Deals

US IPO fundraising reached approximately $125 billion in 2026, surpassing the previous annual high of $120 billion set in 2021, according to Goldman Sachs analysis^[1]. But the headline number masks a striking compositional difference: only 53 deals above $25 million have priced this year, compared to 168 in 1999 and 139 in 2021^[1]. Fewer companies are going public, but the ones that do are raising enormous sums.

Total US equity issuance — combining IPOs, secondary offerings, convertible bonds, and SPACs — reached approximately $700 billion, according to Goldman Sachs Chief US Equity Strategist Ben Snyder. That figure represents about 1% of Russell 3000 market capitalization, in line with the 2015–2019 average and below 2021’s roughly 1.5% and the dot-com peak of 2%^[2].

The most recent week brought fresh supply across sectors. Jersey Mike’s Subs (JMKE), backed by Blackstone, priced 43.5 million shares at $23 on July 30, raising $1 billion in an offering that was 68% secondary^[3]. The stock fell approximately 6% in its NYSE debut^[3]. Ionic Digital (IOND), a bitcoin mining and AI infrastructure company formed from Celsius Mining assets, began trading on Nasdaq July 28 via direct listing and surged 26%, reaching an implied valuation of roughly $2.8 billion^[4]. Apnimed (APMD), a late-stage sleep apnea drug developer, priced an upsized 12 million share offering at $16 — the high end — raising $192 million^[5].

Next week’s calendar adds four more names: Attovia Therapeutics (ATTO) targeting a $200 million raise on August 5, Braveheart Bio (BRVE) at $300 million, OceanLight Acquisition Corp (OCLT), a $100 million SPAC, and Vogenx (VOGX) at $75 million — all on August 6^[6].

SpaceX: The $123 Billion Unlock

The single largest lockup event of the year arrives this week. SpaceX, which priced its IPO at $135 per share on June 11 and began trading June 12, has already fallen below its offering price — closing below $135 for the eighth consecutive session by mid-July^[7].

The first phase of the company’s lockup expires August 6, two days after SpaceX reports earnings on August 4^[7]. Approximately $123 billion in previously restricted shares becomes eligible for sale, and Morningstar reports that the unlock schedule could bring more than $100 billion worth of SpaceX stock to market in the coming months as subsequent tranches release^[7].

The mechanics matter. When a company goes public, only a fraction of shares are immediately tradable. The remainder sit behind lockup agreements that typically expire 180 days post-listing. Once those restrictions lift, the tradable float can increase sharply. In SpaceX’s case, the pre-IPO investors who become eligible to sell on August 6 hold shares worth more than most companies’ entire market capitalizations. As the available share count rises, index funds that track market-cap-weighted benchmarks will need to increase their SpaceX weightings, potentially creating a feedback loop of forced buying against a wave of insider selling^[7].

SpaceX is not alone. Spyglass Pharma’s (SGP) lockup expires August 5, with 9.375 million shares from its February IPO becoming tradable^[8]. Fundrise Innovation Fund (VCX) accelerated its lockup expiration from September 14 to August 13, concluding that the lockup had already served its purpose of supporting orderly price discovery^[8].

Buybacks Lose Their Share-Count Punch

The traditional offset to equity supply — corporate buybacks — is still running at record headline numbers but losing its most important mechanism.

Corporate buyback announcements totaled $960 billion year-to-date in 2026, with Goldman Sachs projecting full-year volume at approximately $1.3 trillion^[2]. NVIDIA alone increased its buyback authorization by $80 billion^[2].

But the S&P 500’s total share count is rising again, despite companies continuing to spend heavily on repurchases^[9]. The difference between buyback spending and actual share reduction is the crux: companies can announce enormous repurchase programs while simultaneously issuing new stock through employee compensation, acquisitions, and secondary sales. In Big Tech, where stock-based compensation is a major component of pay, buybacks are increasingly just treading water on share count.

Fidelity estimates buybacks have declined to roughly 31% of earnings as borrowing rises and companies invest in AI infrastructure^[9]. Alphabet’s planned $80 billion stock sale, coming as the company ramps AI investment after years as one of the market’s largest buyers of its own shares, is a vivid example of the pivot^[9]. Amazon’s free cash flow fell 95% over the past year because the company spent nearly all its additional operating cash on AI infrastructure^[9].

Barclays estimates that spending by major hyperscalers could exceed $1 trillion annually by 2028^[10]. The investment bank argues that the reduction in buybacks does not necessarily represent a negative signal — markets are increasingly rewarding companies for credible AI growth strategies rather than short-term capital returns^[10]. But NDR has flagged waning buybacks as a warning sign for the S&P 500, noting that repurchases have fallen from their 2025 peaks^[11].

The net effect: buybacks are projected to absorb supply in 2026, but Goldman’s Snyder notes that “the math becomes more difficult in 2027 when lockups for stocks listed in 2026 expire” and “the supply-demand balance is clearly moving in a negative direction”^[2].

The Liquidity Buffer Is Gone

The Federal Reserve’s overnight reverse repo (ON RRP) facility — the system’s excess-cash buffer that peaked above $2 trillion in 2023 — has collapsed to approximately $1 billion, effectively at zero^[12]. Bank reserves at the Fed stand at roughly $2.985 trillion^[12].

The depletion matters because the ON RRP facility historically served as a liquidity shock absorber: when cash was abundant, money market funds parked it at the Fed; when cash tightened, that balance drained back into the system. With the facility now functionally empty, there is no buffer left. Any liquidity shock — a surge in Treasury issuance, a reserve drain, or a spike in margin demand from the lockup-driven trading volume — has to be absorbed by bank reserves, which are finite.

Market Structure: Resilient but Shifting

Liquidnet’s Q2 2026 US Liquidity Landscape report describes a market that remains resilient but carries “underlying structural complexities”^[13]. The S&P 500 rallied 17% over six weeks heading into mid-2026, with the market on track for a fourth consecutive year of double-digit gains — something that has happened only three times before, most recently during the Dot-Com Bubble^[13].

But beneath the surface, execution conditions have deteriorated. Bid-offer spreads remain elevated, and April’s average depth of book fell 32% compared with January 2025^[13]. Off-exchange volume has fallen to 34% of the market from 38% in 2025, while ATS volumes have risen to 14%^[13]. ETF volumes reached a record 29% of total market volume in March, yet the closing auction — historically the dominant liquidity event for institutional traders — accounted for just 6.6% of total US volumes^[13]. After-hours trading rose nearly 70% between 2024 and 2025 and now regularly exceeds 10% of total market trading^[13].

The Supply-Demand Ledger

Putting the pieces together, here is where the balance stands:

What to Watch Next

1. SpaceX earnings (Aug 4) and lockup expiry (Aug 6): The gap between these two events is the most concentrated supply test of the year. If pre-IPO investors sell aggressively on August 6 and the stock holds, it signals the market is absorbing supply. If it breaks lower, Goldman’s warning about “newly listed stocks showing noticeably poor performance immediately after listing” as a supply-demand signal comes into play^[2].

2. Next week’s IPO performance (ATTO, BRVE, OCLT, VOGX): Four new deals price the week of August 4–6. A clean reception keeps the issuance window open. Discounts or postponements would be an early signal that the market is choking on supply.

3. Q2 2026 buyback announcements: The next round of corporate buyback authorizations arrives with Q2 earnings season. If Big Tech announces further reductions — or, as Alphabet has signaled, new stock issuance instead of buybacks — the demand side of the ledger weakens further.

4. Fed balance sheet trajectory: With the ON RRP depleted, any acceleration in QT or a Treasury refunding surge would draw directly from bank reserves. The next FOMC meeting and Treasury refunding announcement are the checkpoints.

5. S&P 500 share count: Watch diluted shares outstanding for the mega-cap technology companies. If the share count continues to rise despite buyback spending, the structural support that drove the prior decade’s EPS growth is gone.

The base case here is roughly 60/40 that the market absorbs this supply without a meaningful break — buybacks at $1.3 trillion are still enormous, the 2026 issuance total is historically average as a percentage of market cap, and Goldman’s Ritter notes that “given the overall size of the US stock market, the likelihood of serious indigestion remains low”^[2]. But the 40% case is the one worth watching: if SpaceX’s unlock triggers broad selling across newly listed names, if buybacks continue to lose their share-count punch at the same time AI capex eats more free cash flow, and if the Fed’s drained liquidity buffer means there is no cushion to absorb the resulting volume, the supply-demand balance that sustained four years of double-digit gains starts to wobble. The market has a self-correcting mechanism — excess supply constrains future issuance^[2] — but that mechanism works by making it harder to go public, which is a backward-looking signal, not a forward-looking one.

The IPO window is open. The question is whether it stays open wide enough, long enough, for the supply already queued behind it.